lapatinib has been researched along with everolimus in 24 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 5,631 | 1,289 | 4,579 |
Protein | Taxonomy | lapatinib (IC50) | everolimus (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 2 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (16.67) | 29.6817 |
2010's | 16 (66.67) | 24.3611 |
2020's | 4 (16.67) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Fricker, J | 1 |
Hortobagyi, GN; Pusztai, L; Ravdin, PM; Ross, JS; Slodkowska, EA; Symmans, WF | 1 |
Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Noël-Hudson, MS; Thomas-Bourgneuf, L | 1 |
Hede, K | 1 |
Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hilfrich, J; Kreienberg, R; Loibl, S; Nekljudova, V; Solbach, C; Strumberg, D; Untch, M; von Minckwitz, G | 1 |
Korman, DB | 1 |
de Azambuja, E; Metzger-Filho, O | 1 |
Bigot, L; Boige, V; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Goéré, D; Gonin, P; Marion, S; Noël-Hudson, MS; Polrot, M | 1 |
Ito, Y | 1 |
Christensen, SD; Chung, V; Gadgeel, SM; Hoering, A; Kingsbury, L; Kurzrock, R; Lew, DL; LoRusso, P; Smith, DC; Synold, TW | 1 |
Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
Gyõrffy, B; Mihály, Z | 1 |
Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
Mehta, A; Tripathy, D | 1 |
Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
Buskens, E; de Bock, GH; Greuter, MJW; Koleva-Kolarova, RG; Oktora, MP; Reyners, AKL; Robijn, AL | 1 |
Abbadi, S; Blakeley, JO; Bonne, N; Brem, H; Giovannini, M; Itzoe, M; Paldor, I; Rodriguez, FJ; Rowshanshad, D; Tyler, BM; Vigilar, V; Ye, X | 1 |
Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW | 1 |
Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
Ge, L; Gong, H; Hou, L; Jin, X; Leng, G; Li, C; Li, T; Liu, Y; Ma, L; Niu, S; Su, Y; Zhang, H; Zhang, L; Zhao, L | 1 |
Barbolini, M; Canino, F; Dominici, M; Moscetti, L; Omarini, C; Piacentini, F; Toss, A; Vici, P | 1 |
12 review(s) available for lapatinib and everolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Evidence-Based Medicine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Lapatinib; Neoplasm Staging; Polymerase Chain Reaction; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Sirolimus; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2009 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Lapatinib; Life Expectancy; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2017 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Everolimus; Humans; Lapatinib; Network Meta-Analysis; Nivolumab; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2022 |
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Hormones; Humans; Lapatinib; Receptor, ErbB-2 | 2022 |
1 trial(s) available for lapatinib and everolimus
Article | Year |
---|---|
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Everolimus; Female; Humans; Incidence; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; United States; Young Adult | 2013 |
11 other study(ies) available for lapatinib and everolimus
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Blotting, Western; Digoxin; Everolimus; Female; Intestinal Mucosa; Intestines; Lapatinib; Mice; Mice, Knockout; Quinazolines; Sirolimus; Substrate Specificity; Tissue Distribution | 2009 |
Gastric cancer: trastuzumab trial results spur search for other targets.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2009 |
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Everolimus; Female; Humans; Lapatinib; Quinazolines; Sirolimus | 2011 |
[Breast cancer therapy with combination of endocrine and target drugs].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Sirolimus; Trastuzumab | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Colorectal Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Mice; Mice, Nude; Mutation; Quinazolines; ras Proteins; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Everolimus; Lapatinib; Mice; Mice, Nude; Mice, Transgenic; Models, Statistical; Neoplasm Transplantation; Neurilemmoma; Neurofibromatosis 2; Peripheral Nervous System Neoplasms; Pyrimidines; Quinazolines; Sciatic Nerve; Time Factors | 2017 |
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2018 |
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |